A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants

May 22, 2025 updated by: Janssen Research & Development, LLC

An Open-Label, Randomized, Crossover Study to Evaluate the Relative Oral Bioavailability, Pharmacokinetics, and Food Effect After Single Dose (for Part 1, Part 3, Part 4 and Part 5) or Multiple-Dose (for Part 2) Administration of JNJ-70033093 (Milvexian) in Healthy Adult Participants Using Tablet, Capsule and Dispersed Tablet Formulations

The purpose of this study is to evaluate the relative bioavailability and food effect of a single dose of milvexian administered as direct compression (DC) oral tablets and roller compacted (RC) oral tablets compared with milvexian administered as Phase 2 oral capsules (Part 1) and of new concept tablets consisting of a single dose of milvexian administered as oral Tablet 1 and Tablet 2 compared with milvexian administered as Phase 2 oral capsules (Part 3) in healthy participants under fasting and fed conditions; to characterize the pharmacokinetics (PK) of multiple twice daily (BID) doses for 5 days of milvexian administered as DC oral tablets and Phase 2 oral capsules in healthy participants (Part 2) and to assess the effects of dosing time and food timing on the PK of single-dose of milvexian Phase 3 oral tablet formulation in healthy participants (Part 4) and to evaluate the relative bioavailability of a single dose of milvexian administered as oral film-coated DC whole tablets, oral film-coated DC tablets dispersed in water and then mixed with apple sauce, and oral film-coated DC tablets dispersed in water and administered as a suspension using a nasogastric (NG) tube in healthy participants under fasting conditions (Part 5).

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

115

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Utah
      • Salt Lake City, Utah, United States, 84124
        • PRA Health Sciences

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years to 51 years (Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Healthy on the basis of physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at screening and on Day -1 of Treatment Period 1. If there are abnormalities, the investigator may decide that the abnormalities or deviations from normal are not clinically significant, in which case the participant may be included
  • Body mass index (BMI equals to [=] weight/height^2) between 18 and 30 kilograms per meter square (kg/m^2) (inclusive), and body weight not less than 50 kg at screening
  • Healthy on the basis of safety laboratory tests performed at screening and on Day -1 of Treatment Period 1. If the results of the safety laboratory tests are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant except as specified in Exclusion Criteria 2. This determination must be recorded in the participant's source documents and initialed by the investigator
  • A woman must have a negative highly sensitive serum (beta-human chorionic gonadotropin [beta-hCG]) at screening and urine pregnancy test on Day 1 of Treatment Period 1
  • Before randomization, a woman must be either: a) Not of childbearing potential defined as: postmenopausal: A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level greater than (>) 40 international units per liter IU/L or milli-international units per milliliter (mIU/mL) in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal replacement therapy (HRT), however in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient; permanently sterile: Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy; b) Of childbearing potential and; practicing a highly effective method of contraception (failure rate of less than [<] 1 percent [%] per year when used consistently and correctly) for at least 3 months prior to the study entry and; agrees to remain on a highly effective method of contraception throughout the study and for at least 34 days after the last dose of study drug
  • During the study, a man who is sexually active with a woman of childbearing potential or with a woman who is pregnant must agree to use a barrier method of contraception (example, condom with spermicidal foam/gel/ film/cream/suppository)

Exclusion Criteria:

  • History of any known illness that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant or that could prevent, limit or confound the protocol-specified assessments. This may include but is not limited to any known bleeding or clotting disorder, a history of arterial or venous thrombosis, liver or renal dysfunction, significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, neoplasm, metabolic disturbances, or poor venous access
  • Clinically significant abnormal values for hematology, coagulation, clinical chemistry, or urinalysis at screening or on Day -1 of Treatment Period 1 as determined by the investigator or appropriate designee. Any of the following laboratory results outside of the normal ranges specified below at screening or Day -1 of Treatment Period 1 which must be confirmed by repeat: Hemoglobin or hematocrit less than (<) lower limit of normal; Platelet count < lower limit of normal; activated partial thromboplastin time (aPTT) or prothrombin time (PT) >1.2*upper limit of normal (ULN)
  • Use of any agent, including but not limited to non-steroidal anti-inflammatory drugs (NSAIDs), aspirin or other anti-platelet agents, anticoagulants, fish oil capsules, ginkgo or any agent that can potentially increase the risk of bleeding within 14 days prior to the first dose of study drug administration
  • History of any clinically significant drug or food allergies (such as anaphylaxis or hepatotoxicity) and known allergy to the study drugs or any of the excipients of the formulation
  • History of allergy to or unwillingness to consume any component of the standardized high-fat breakfast menu to be provided in this study
  • Woman with history of excessive menstrual bleeding as determined by the investigator or appropriate designee
  • Does not tolerate venipuncture

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Part 1A: Treatment Sequence ABC
Participants will receive a single oral Dose 1 of milvexian as direct compression (DC) tablets under fasting conditions (Treatment A) in Treatment Period 1, followed by a single oral Dose 1 of milvexian as roller compacted (RC) tablets under fasting conditions (Treatment B) in Treatment Period 2 and then a single oral Dose 1 of milvexian Phase 2 oral capsules under fasting conditions (Treatment C) in Treatment Period 3 on Day 1 of each Treatment Period during Part 1A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 1A: Treatment Sequence BCA
Participants will receive Treatment B in Treatment Period 1, followed by Treatment C in Treatment Period 2 and then Treatment A in Treatment Period 3 on Day 1 of each Treatment Period during Part 1A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 1A: Treatment Sequence CAB
Participants will receive Treatment C in Treatment Period 1, followed by Treatment A in Treatment Period 2 and then Treatment B in Treatment Period 3 on Day 1 of each Treatment Period during Part 1A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 1A: Treatment Sequence ACB
Participants will receive Treatment A in Treatment Period 1, followed by Treatment C in Treatment Period 2 and then Treatment B in Treatment Period 3 on Day 1 of each Treatment Period during Part 1A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 1A: Treatment Sequence BAC
Participants will receive Treatment B in Treatment Period 1, followed by Treatment A in Treatment Period 2 and then Treatment C in Treatment Period 3 on Day 1 of each Treatment Period during Part 1A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 1A: Treatment Sequence CBA
Participants will receive Treatment C in Treatment Period 1 followed by Treatment B in Treatment Period 2 and then Treatment A in Treatment Period 3 on Day 1 of each Treatment Period during Part 1A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 1B: Treatment Sequence DEF
Participants will receive a single oral Dose 1 of milvexian as DC oral tablets under fed conditions (Treatment D) in Treatment Period 1, followed by a single oral Dose 1 of milvexian as RC oral tablets under fed conditions (Treatment E) in Treatment Period 2 and then a single oral Dose 1 of milvexian as Phase 2 oral capsules under fed conditions (Treatment F) in Treatment Period 3 on Day 1 of each Treatment Period during Part 1B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 1B: Treatment Sequence EFD
Participants will receive Treatment E in Treatment Period 1, followed by Treatment F in Treatment Period 2 and then Treatment D in Treatment Period 3 on Day 1 of each Treatment Period during Part 1B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 1B: Treatment Sequence FDE
Participants will receive Treatment F in Treatment Period 1, followed by Treatment D in Treatment Period 2 and then Treatment E in Treatment Period 3 on Day 1 of each Treatment Period during Part 1B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 1B: Treatment Sequence DFE
Participants will receive Treatment D in Treatment Period 1, followed by Treatment F in Treatment Period 2 and then Treatment E in Treatment Period 3 on Day 1 of each Treatment Period during Part 1B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 1B: Treatment Sequence EDF
Participants will receive Treatment E in Treatment Period 1, followed by Treatment D in Treatment Period 2 and then Treatment F in Treatment Period 3 on Day 1 of each Treatment Period during Part 1B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 1B: Treatment Sequence FED
Participants will receive Treatment F in Treatment Period 1, followed by Treatment E in Treatment Period 2 and then Treatment D in Treatment Period 3 on Day 1 of each Treatment Period during Part 1B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 2A: Treatment Sequence GH
Participants will receive twice daily (BID) oral Dose 1 of milvexian DC oral tablets (Treatment G) in Treatment Period 1, followed by BID oral Dose 1 of milvexian Phase 2 oral capsule (Treatment H) in Treatment Period 2 up to Day 5 in each Treatment Period during Part 2A. There will be a wash-out period of more than 5 days between the evening dose of Day 5 of Treatment Period 1 and the morning dose of Day 1 of Treatment Period 2.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 2A: Treatment Sequence HG
Participants will receive Treatment H in Treatment Period 1, followed by Treatment G in Treatment Period 2 up to Day 5 in each Treatment Period during Part 2A. There will be a wash-out period of more than 5 days between the evening dose of Day 5 of Treatment Period 1 and the morning dose of Day 1 of Treatment Period 2.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 2B: Treatment Sequence IJ
Participants will receive BID oral Dose 2 of milvexian DC oral tablet (Treatment I) in Treatment Period 1, followed by BID oral Dose 2 of milvexian Phase 2 oral capsule (Treatment J) in Treatment Period 2 up to Day 5 in each Treatment Period during Part 2B. There will be a wash-out period of more than 5 days between the evening dose of Day 5 of Treatment Period 1 and the morning dose of Day 1 of Treatment Period 2.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 2B: Treatment Sequence JI
Participants will receive Treatment J in Treatment Period 1, followed by Treatment I in Treatment Period 2 up to Day 5 in each Treatment Period during Part 2B. There will be a wash-out period of more than 5 days between the evening dose of Day 5 of Treatment Period 1 and the morning dose of Day 1 of Treatment Period 2.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 3A: Treatment Sequence KLM
Participants will receive single oral Dose 1 of milvexian as oral Tablet 1 under fasting conditions (Treatment K) in Treatment Period 1, followed by single oral Dose 1 of milvexian oral Tablet 2 under fasting conditions (Treatment L) in Treatment Period 2 and then single oral Dose 1 of milvexian as Phase 2 oral capsules under fasting conditions (Treatment M) in Treatment Period 3 on Day 1 in each Treatment Period during Part 3A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 3A: Treatment Sequence LMK
Participants will receive Treatment L in Treatment Period 1, followed by Treatment M in Treatment Period 2 and then Treatment K in Treatment Period 3 on Day 1 of each Treatment Period during Part 3A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 3A: Treatment Sequence MKL
Participants will receive Treatment M in Treatment Period 1, followed by Treatment K in Treatment Period 2 and then Treatment L in Treatment Period 3 on Day 1 in each Treatment Period during Part 3A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 3A: Treatment Sequence KML
Participants will receive Treatment K in Treatment Period 1, followed by Treatment M in Treatment Period 2 and then Treatment L in Treatment Period 3 on Day 1 in each Treatment Period during Part 3A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 3A: Treatment Sequence LKM
Participants will receive Treatment L in Treatment Period 1, followed by Treatment K in Treatment Period 2 and then Treatment M in Treatment Period 3 on Day 1 in each Treatment Period during Part 3A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 3A: Treatment Sequence MLK
Participants will receive Treatment M in Treatment Period 1, followed by Treatment L in Treatment Period 2 and then Treatment K in Treatment Period 3 on Day 1 in each Treatment Period during Part 3A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 3B: Treatment Sequence NOP
Participants will receive single oral Dose 1 of milvexian oral Tablet 1 under fed conditions (Treatment N) in Treatment Period 1, followed by single oral Dose 1 of milvexian oral Tablet 2 under fed conditions (Treatment O) in Treatment Period 2 and then single oral Dose 1 of milvexian Phase 2 oral capsule under fed conditions (Treatment P) in Treatment Period 3 on Day 1 in each Treatment Period during Part 3B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 3B: Treatment Sequence OPN
Participants will receive Treatment O in Treatment Period 1, followed by Treatment P in Treatment Period 2 and then Treatment N in Treatment Period 3 on Day 1 in each Treatment Period during Part 3B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 3B: Treatment Sequence PNO
Participants will receive Treatment P in Treatment Period 1, followed by Treatment N in Treatment Period 2 and then Treatment O in Treatment Period 3 on Day 1 in each Treatment Period during Part 3B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 3B: Treatment Sequence NPO
Participants will receive Treatment N in Treatment Period 1, followed by Treatment P in Treatment Period 2 and then Treatment O in Treatment Period 3 on Day 1 in each Treatment Period during Part 3B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 3B: Treatment Sequence ONP
Participants will receive Treatment O in Treatment Period 1, followed by Treatment N in Treatment Period 2 and then Treatment P in Treatment Period 3 on Day 1 in each Treatment Period during Part 3B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 3B: Treatment Sequence PON
Participants will receive Treatment P in Treatment Period 1, followed by Treatment O in Treatment Period 2 and then Treatment N in Treatment Period 3 on Day 1 in each Treatment Period during Part 3B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 4 A: Treatment Sequence QRS
Participants will receive single oral Dose 1 of milvexian as Phase 3 oral tablets under fasting conditions (Treatment Q) in Treatment Period 1, followed by single oral Dose 1 of milvexian as Phase 3 oral tablets under fed conditions (Treatment R) in Treatment Period 2 and then single oral Dose 1 of milvexian as Phase 3 oral tablets under fed conditions (Treatment S) in Treatment Period 3 on Day 1 of each Treatment Period during Part 4A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 4A: Treatment Sequence RSQ
Participants will receive Treatment R in Treatment Period 1, followed by Treatment S in Treatment Period 2 and then Treatment Q in Treatment Period 3 on Day 1 of each Treatment Period during Part 4A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 4A: Treatment Sequence SQR
Participants will receive Treatment S in Treatment Period 1, followed by Treatment Q in Treatment Period 2 and then Treatment R in Treatment Period 3 on Day 1 of each Treatment Period during Part 4A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 4A: Treatment Sequence QSR
Participants will receive Treatment Q in Treatment Period 1, followed by Treatment S in Treatment Period 2 and then Treatment R in Treatment Period 3 on Day 1 of each Treatment Period during Part 4A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 4A: Treatment Sequence RQS
Participants will receive Treatment R in Treatment Period 1, followed by Treatment Q in Treatment Period 2 and then Treatment S in Treatment Period 3 on Day 1 of each Treatment Period during Part 4A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 4A: Treatment Sequence SRQ
Participants will receive Treatment S in Treatment Period 1, followed by Treatment R in Treatment Period 2 and then Treatment Q in Treatment Period 3 on Day 1 of each Treatment Period during Part 4A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 4B: Treatment Sequence TU
Participants will receive single oral Dose 1 of milvexian as Phase 3 oral tablet under fed conditions (Treatment T) in Treatment Period 1, followed by single oral Dose 2 of milvexian as Phase 3 oral tablet under fed conditions (Treatment U) in Treatment Period 2 on Day 1 of each Treatment Period during Part 4B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 4B: Treatment Sequence UT
Participants will receive Treatment U in Treatment Period 1, followed by Treatment T in Treatment Period 2 on Day 1 of each Treatment Period during Part 4B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Subpart 4A: Treatment Sequence VW
All participants of Subpart 4A will undertake a mandatory taste assessment on Day 5 of period 3 or Day 15 before the discharge and will receive milvexian tablet dispersed in water without a sweetener orally via syringe (Treatment V) in Treatment Period 1, followed by milvexian tablet dispersed in water with sucralose sweetener orally via syringe (Treatment W) in Treatment Period 2. Participants will cleanse their palates using 2 rinse of mineral water and one unsalted cracker and wait for a time interval of at least 1-2 hours from start of dosing before the next taste round.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Subpart 4A: Treatment Sequence WV
All participants of Subpart 4A will undertake a mandatory taste assessment on Day 5 of period 3 or Day 15 before the discharge and will receive Treatment W in Treatment Period 1, followed by Treatment V in Treatment Period 2. Participants will cleanse their palates using 2 rinse of mineral water and one unsalted cracker and wait for a time interval of at least 1-2 hours from start of dosing before the next taste round.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 5: Treatment Sequence XYZ
Participants will receive a single oral Dose 1 of milvexian as DC whole tablets under fasting conditions (Treatment X) in Treatment Period 1 followed by a single oral Dose 1 of milvexian as DC tablets dispersed in water and then mixed with apple sauce under fasting conditions (Treatment Y) in Treatment Period 2 and then a single oral Dose 1 of milvexian as DC tablets dispersed in water administered through a nasogastric (NG) tube under fasting conditions (Treatment Z) in Treatment Period 3 on Day 1 of each Treatment Period during Part 5. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 5: Treatment Sequence YZX
Participants will receive Treatment Y in Treatment Period 1 followed by Treatment Z in Treatment Period 2 and then Treatment X in Treatment Period 3 on Day 1 of each Treatment Period during Part 5. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 5: Treatment Sequence ZXY
Participants will receive Treatment Z in Treatment Period 1 followed by Treatment X in Treatment Period 2 and then Treatment Y in Treatment Period 3 on Day 1 of each Treatment Period during Part 5. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 5: Treatment Sequence XZY
Participants will receive Treatment X in Treatment Period 1 followed by Treatment Z in Treatment Period 2 and then Treatment Y in Treatment Period 3 on Day 1 of each Treatment Period during Part 5. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 5: Treatment Sequence YXZ
Participants will receive Treatment Y in Treatment Period 1 followed by Treatment X in Treatment Period 2 and then Treatment Z in Treatment Period 3 on Day 1 of each Treatment Period during Part 5. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177
Experimental: Part 5: Treatment Sequence ZYX
Participants will receive Treatment Z in Treatment Period 1 followed by Treatment Y in Treatment Period 2 and then Treatment X in Treatment Period 3 on Day 1 of each Treatment Period during Part 5. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
Drug: Milvexian
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Other Names:
  • JNJ-70033093, BMS-986177

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Area Under the Plasma Concentration-time Curve of Milvexian from Time Zero to Infinity (AUC [0-Infinity])
Time Frame: Up to 16 months
AUC (0-infinity) is defined as area under the plasma concentration-time curve of milvexian from time zero to infinity after administration.
Up to 16 months
Part 2: Area under the Plasma Concentration-time Curve of Milvexian From Time Zero to Time of Last Quantifiable Concentration (AUC [0-Last])
Time Frame: Up to 16 months
AUC (0-last) is defined as area under the plasma concentration-time curve of milvexian from time zero to time of last quantifiable concentration after administration.
Up to 16 months
Maximum Observed Analyte Concentration (Cmax) of Milvexian
Time Frame: Up to 16 months
Cmax is defined as maximum observed analyte concentration of milvexian.
Up to 16 months
Parts 1 and 3: AUC (0-Infinity) of Milvexian (Food effect)
Time Frame: Up to 16 months
AUC (0-infinity) is defined as area under the plasma concentration-time curve of milvexian from time zero to infinity after administration.
Up to 16 months
Parts 1 and 3: AUC (0-Last) of Milvexian (Food effect)
Time Frame: Up to 16 months
AUC (0-last) is defined as area under the plasma concentration-time curve of milvexian from time zero to time of last quantifiable concentration after administration.
Up to 16 months
Parts 1 and 3: Cmax of Milvexian (Food effect)
Time Frame: Up to 16 months
Cmax is defined as maximum observed analyte concentration of milvexian.
Up to 16 months
Actual Sampling Time to Reach the Maximum Observed Analyte Concentration (Tmax) of Milvexian
Time Frame: Up to 16 months
Tmax is defined as the actual sampling time to reach the maximum observed analyte concentration of milvexian.
Up to 16 months
Parts 1 and 3: Tmax of Milvexian (Food effect)
Time Frame: Up to 16 months
Tmax is defined as the actual sampling time to reach the maximum observed analyte concentration of milvexian.
Up to 16 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability
Time Frame: Up to 16 months
An AE is any untoward medical occurrence in a clinical study participant administered a investigational or non-investigational medicinal product. An AE does not necessarily have a causal relationship with the treatment.
Up to 16 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Janssen Research & Development, LLC

Investigators

  • Study Director: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 14, 2021

Primary Completion (Actual)

May 6, 2022

Study Completion (Actual)

July 12, 2022

Study Registration Dates

First Submitted

April 12, 2021

First Submitted That Met QC Criteria

April 12, 2021

First Posted (Actual)

April 14, 2021

Study Record Updates

Last Update Posted (Actual)

May 23, 2025

Last Update Submitted That Met QC Criteria

May 22, 2025

Last Verified

May 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • CR108999
  • 70033093THR1008 (Other Identifier: Janssen Research & Development, LLC)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on Milvexian

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe